Imbio PHA (4.0.0) vs inHEART Models
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your primary need is rapid, automated quantification of cardiac structures from CT pulmonary angiogram (CTPA) scans. This tool is ideal for aiding in the diagnosis and risk stratification of conditions like pulmonary embolism and hypertension by providing quick, objective measurements of ventricular and arterial diameters and ratios. It streamlines the initial assessment workflow by integrating seamlessly with existing DICOM tools and generating summary reports.
View Imbio PHA (4.0.0) →Choose inHEART Models if…
Choose inHEART Models if you require highly detailed, AI-driven 3D digital twin models of the heart for advanced pre-procedural planning and optimization of image-guided cardiac ablation procedures. This software is particularly well-suited for complex arrhythmia cases, such as ventricular tachycardia, where precise anatomical understanding and integration with electroanatomic mapping systems can significantly reduce procedure times and improve long-term patient outcomes.
View inHEART Models →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | inHEART Models |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Cloud-based |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA emphasizes a fully automated, rapid assessment that integrates seamlessly into existing DICOM workflows, requiring no new user interfaces for clinicians, which prioritizes efficiency and minimal disruption to clinical practice. While inHEART offers an intuitive interface and rapid model generation, its cloud-only deployment and potential limitations with certain EAM systems or offline access could present usability challenges in some clinical settings.
Clinical Value
inHEART ModelsinHEART Models demonstrates a stronger, more quantifiable clinical value by showing a potential to significantly reduce VT procedure times by 60% and recurrence rates by 38%. While Imbio PHA provides valuable automated measurements for diagnosis and risk stratification of pulmonary embolism and hypertension, its clinical impact is not as directly quantified in terms of patient outcomes or procedural efficiency in the provided data.
Pricing & Value
TieBoth tools have opaque pricing, requiring direct contact with the vendor for details, making a direct comparison of overall value difficult. While inHEART Models benefits from a newly established CMS reimbursement code (C9793) which could enhance its value proposition, specific cost-effectiveness data for either tool are not publicly available.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA is more enterprise-ready due to its explicit third-party HIPAA certification and the flexibility of offering both cloud and on-premise deployment options. In contrast, inHEART Models is cloud-based only, and while SOC2 compliant, its HIPAA and BAA readiness are inferred rather than explicitly stated, which may lead to additional data governance scrutiny for some enterprises.
Innovation
inHEART ModelsinHEART Models is more innovative. Its creation of a 'detailed 3D digital twin of the heart' for pre-procedural planning and optimization of complex cardiac ablation procedures represents a more advanced and transformative application of AI in cardiology compared to Imbio PHA's automated measurements of cardiac structures.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA has a stronger showing for support and documentation, explicitly stating 24/7/365 global support via multiple channels and offering user manuals and product documentation upon request. While inHEART provides contact information and educational resources like webinars and publications, its support structure and documentation availability are not as clearly detailed.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | inHEART Models |
|---|---|---|
| Name | Imbio PHA (4.0.0) | inHEART Models |
| Primary Use Case | Measures cardiac structures from CTPA scans to assess right ventricular dilation and aid in diagnosis and risk stratification of pulmonary embolism and hypertension. | Creates detailed 3D digital twin models of the heart from CT/MR images, optimizing planning and execution of image-guided cardiac ablation procedures. |
| Company | Imbio | inHEART |
| Key AI Functionality | Automated measurement of right and left ventricle diameters; Automated measurement of main pulmonary artery and aorta diameters; Calculates RV/LV and PA/Ao ratios; Utilizes artificial intelligence algorithms for anatomical identification and measurement. | AI-driven digital twin of the heart; Automated segmentation of CT and MR images; Highly detailed, interactive 3D cardiac models. |
| Output/Integration | Generates annotated DICOM images; Provides summary reports in PDF format; Integrates with native DICOM tools and workflows. | Seamless integration with major electroanatomic mapping (EAM) systems (Cartou00ae, Rhythmiau2122, Ensiteu2122, Afferau2122); Cloud-based platform for interactive exploration. |
| Target Medical Images | CT pulmonary angiogram (CTPA) scans | CT/MR images |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and inHEART Models.